Latest AI (Artificial Intelligence) News

📅December 10, 2025 at 1:00 AM

AI is accelerating biotech and drug discovery through autonomous labs, physics-guided models, and national initiatives like the US Genesis Mission, while major AI firms roll out powerful new models and chip deals.

US launches Genesis Mission to accelerate AI-driven scientific discovery

The US has launched the Genesis Mission, a national AI R&D initiative to centralize scientific discovery using federal datasets, AI agents, and national labs to accelerate breakthroughs in biotech, advanced manufacturing, and quantum science , . The mission aims to build an integrated AI platform to train scientific foundation models and automate research workflows across critical technology sectors , .

DoE commissions world’s largest autonomous microbial lab

The US Department of Energy has commissioned the Anaerobic Microbial Phenotyping Platform (AMP2), built by Ginkgo Bioworks, said to be the world’s largest autonomous-capable system for anaerobic microbial experimentation . AMP2 uses automation and AI to identify, grow, and optimize microbes for chemicals, biomaterials, fuels, and mineral extraction in days or weeks instead of years .

AI and autonomous labs boost biotech research and the bioeconomy

Autonomous labs and AI are being used to support biotech research and the US bioeconomy, with AI analytical tools analyzing findings in real time and redirecting experiments faster than humans can . These systems allow more experiments and larger datasets, enabling faster, more efficient conclusions than traditional methods .

AI and physics combine to shape next wave of drug discovery

The next wave of AI-assisted drug discovery combines generative AI with computational physics and structure-based modeling to design novel, first-in-class molecules from scratch . This physics-guided approach enables discovery even when experimental data are minimal, using 3D structural information rather than relying solely on historical compound data .

AI-designed drugs and antibodies enter clinical trials

Just a year after the first AI-designed protein, scientists are preparing for clinical trials testing AI-designed antibodies, marking a major milestone in AI-driven biomedicine . AI is increasingly used in target identification, virtual screening, and designing novel molecules that are now advancing into human testing , .

Generative AI identifies new disease pathways and drug candidates

Researchers used a generative AI platform to analyze biological datasets, uncovering an unknown disease pathway and designing new small molecules to modulate it . This demonstrates how AI can accelerate evidence generation and early drug discovery in biopharma .

Nvidia signs $100B landmark deal with OpenAI

Nvidia will supply OpenAI with up to $100 billion worth of H100, H200, and Blackwell GPUs, plus data-center space and power, starting in 2026 . The deal gives OpenAI access to roughly ten gigawatts of compute, comparable to New Zealand’s annual power budget, accelerating the path to superintelligence .

OpenAI releases o3, first model that deliberates before answering

OpenAI launched o3, a new model that pauses to plan, run internal tests, and double-check itself before responding, rather than giving the first answer that comes to mind . This ‘deliberative’ behavior, with response delays from seconds to minutes, represents a shift toward more reasoning-capable AI systems .

Google releases Gemini 3, multimodal model that handles text, images, video, and 3D

Google’s Gemini 3 can process text, images, video, audio, and 3D point clouds in a single model, outperforming earlier specialist AI models . The release marks a major step in unified multimodal AI that can reason across diverse data types .

China’s DeepSeek V3 levels the global AI playing field

DeepSeek released DeepSeek V3 with publicly available weights, matching or beating leading Western closed models in reasoning and coding while using far less compute . The release has democratized access to high-performance AI and intensified global competition in foundational models .

State AGs form AI task force as federal AI push meets state resistance

Following the federal Genesis Mission executive order, state attorneys general have formed an AI task force, reflecting growing tension between federal acceleration of AI R&D and state-level concerns about oversight and civil rights . Related bills like the GENESIS Act and Artificial Intelligence Civil Rights Act highlight the legal and regulatory debate around national AI strategy .

Back to News